The exciting part of this announcement is at the end. "We have already initiated dialogue with NIH to follow NIMA with a study in moderate to severe asthma patients, utilising our inhaled formulation." If Mitchell Glass can succeed in this it will be a real breakthrough for Invion. This is the real bonanza and if the NIH will pay for the next phase, it will relieve most of the money problems!
Ann: Completion of enrolment in INV102 phase II asthma study, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 12.5¢ | $15.62K | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 213400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 57707 | 2 |
View Market Depth
| Last trade - 14.46pm 20/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |